GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events

GTx,Inc. (NASDAQ:GTXI) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On September13, 2017, GTx,Inc. issued a press release announcing top-line clinical trial results demonstrating that a daily dose of enobosarm 3mg (GTx-024) substantially improved stress urinary incontinence in women, as well as related quality of life measurements.

A copy of the press release is furnished as Exhibit99.1 to this Current Report.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

Press Release issued by GTx,Inc. dated September13, 2017


GTX INC /DE/ Exhibit
EX-99.1 2 a17-21968_1ex99d1.htm EX-99.1 Exhibit 99.1   GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence   — Data presented at the International Continence Society Annual Meeting today demonstrated:   * Clinically significant reductions in incontinence episodes per day in all patients completing 12 week treatment   * Reductions in incontinence episodes were sustained for up to 7 months following completion of enobosarm treatment   — Placebo-controlled Phase 2 clinical trial designed to further evaluate enobosarm in postmenopausal women with SUI initiated in August 2017 —   MEMPHIS,…
To view the full exhibit click here

About GTx,Inc. (NASDAQ:GTXI)

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.

An ad to help with our costs